{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:38:46Z","timestamp":1790786326682,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The cardioprotective effects of sodium-glucose cotransporter type 2 (SGLT2) inhibitors have been demonstrated in many studies. However, their benefits for end-stage kidney disease patients, particularly those on peritoneal dialysis, remain unclear. SGLT2 inhibition has shown peritoneal protective effects in some studies, but the mechanisms are still unknown. Herein, we investigated the peritoneal protective mechanisms of Canagliflozin <jats:italic>in vitro<\/jats:italic> by simulating hypoxia with CoCl<jats:sub>2<\/jats:sub> in human peritoneal mesothelial cells (HPMCs) and rats by intraperitoneal injection of 4.25% peritoneal dialysate simulating chronic high glucose exposure. CoCl<jats:sub>2<\/jats:sub> hypoxic intervention significantly increased HIF-1\u03b1 abundance in HPMCs, activated TGF-\u03b2\/p-Smad3 signaling, and promoted the production of fibrotic proteins (Fibronectin, COL1A2, and \u03b1-SMA). Meanwhile, Canagliflozin significantly improved the hypoxia of HPMCs, decreased HIF-1\u03b1 abundance, inhibited TGF-\u03b2\/p-Smad3 signaling, and decreased the expression of fibrotic proteins. Five-week intraperitoneal injection of 4.25% peritoneal dialysate remarkably increased peritoneal HIF-1\u03b1\/TGF-\u03b2\/p-Smad3 signaling and promoted peritoneal fibrosis and peritoneal thickening. At the same time, Canagliflozin significantly inhibited the HIF-1\u03b1\/TGF-\u03b2\/p-Smad3 signaling, prevented peritoneal fibrosis and peritoneal thickening, and improved peritoneal transportation and ultrafiltration. High glucose peritoneal dialysate increased the expression of peritoneal GLUT1, GLUT3 and SGLT2, all of which were inhibited by Canagliflozin. In conclusion, we showed that Canagliflozin could improve peritoneal fibrosis and function by ameliorating peritoneal hypoxia and inhibiting the HIF-1\u03b1\/TGF-\u03b2\/p-Smad3 signaling pathway, providing theoretical support for the clinical use of SGLT2 inhibitors in patients on peritoneal dialysis.<\/jats:p>","DOI":"10.3389\/fphar.2023.1152611","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:06:20Z","timestamp":1683875180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1\u03b1 inhibition"],"prefix":"10.3389","volume":"14","author":[{"given":"Jian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Shan-Jiang","family":"A-Ni-Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha-Sha","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Guang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109778","DOI":"10.1016\/j.cellsig.2020.109778","article-title":"Molecular pathways in peritoneal fibrosis","volume":"75","author":"Balzer","year":"2020","journal-title":"Cell. Signal."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3390\/biom10111573","article-title":"SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate","volume":"10","author":"Balzer","year":"2020","journal-title":"Biomolecules"},{"key":"B3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41581-022-00623-7","article-title":"Epidemiology of peritoneal dialysis outcomes","volume":"18","author":"Bello","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","article-title":"Hypoxia-inducible factor-1\u03b1 is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy","volume":"9","author":"Bessho","year":"2019","journal-title":"Sci. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8968608221096556","DOI":"10.1177\/08968608221096556","article-title":"The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients","volume":"43","author":"Borkum","year":"2022","journal-title":"Perit. Dial. Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lfs.2016.07.018","article-title":"Diabetes and exposure to peritoneal dialysis solutions alter tight junction proteins and glucose transporters of rat peritoneal mesothelial cells","volume":"161","author":"Debray-Garcia","year":"2016","journal-title":"Life Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5283\/epub.1268","article-title":"Regulation of glucose transporters in human peritoneal mesothelial cells","volume":"16","author":"Fischereder","year":"2003","journal-title":"J. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ajpath.2022.03.015","article-title":"Amelioration of murine diabetic nephropathy with a SGLT2 inhibitor is associated with suppressing abnormal expression of hypoxia-inducible factors","volume":"192","author":"Inada","year":"2022","journal-title":"Am. J. Pathol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.26502\/anu.2644-2833047","article-title":"The use of SGLT2 inhibitors in peritoneal dialysis patients: A shade of light on dapagliflozin","volume":"5","author":"K Alhwiesh","year":"2022","journal-title":"Archives Nephrol. Urology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1124\/mol.106.027029","article-title":"Hypoxia-inducible factor-1 (HIF-1)","volume":"70","author":"Ke","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1681\/ASN.2021010080","article-title":"Acquired decline in ultrafiltration in peritoneal dialysis: The role of glucose","volume":"32","author":"Krediet","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2215\/CJN.15371121","article-title":"Relative contributions of pseudohypoxia and inflammation to peritoneal alterations with long-term peritoneal dialysis patients","volume":"17","author":"Krediet","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrneph.2016.181","article-title":"Changes in the worldwide epidemiology of peritoneal dialysis","volume":"13","author":"Li","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.12932\/AP-290519-0570","article-title":"Intermittent hypoxia in rat enhancing peritoneal membrane thickening through HIF-1\u03b1-induced cytokines in peritoneum","volume":"40","author":"Manuprasert","year":"2022","journal-title":"Asian pac. J. Allergy Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/08968608211008095","article-title":"SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis","volume":"41","author":"Martus","year":"2021","journal-title":"Perit. Dial. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"F824-F833","DOI":"10.1152\/ajprenal.00314.2017","article-title":"Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model","volume":"315","author":"Mishima","year":"2018","journal-title":"Am. J. Physiol.-Renal Physiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/0886022X.2015.1127741","article-title":"HIF-1\u03b1 mediates Hypoxia-induced epithelial-mesenchymal transition in peritoneal mesothelial cells","volume":"38","author":"Morishita","year":"2016","journal-title":"Ren. Fail."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur. Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: Modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ki.2009.436","article-title":"Smad3-dependent and -independent pathways are involved in peritoneal membrane injury","volume":"77","author":"Patel","year":"2010","journal-title":"Kidney Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000520894","article-title":"Peritoneal expression of SGLT-2, GLUT1, and GLUT3 in peritoneal dialysis patients","volume":"47","author":"Schricker","year":"2022","journal-title":"Kidney Blood Press. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/j.1582-4934.2011.01493.x","article-title":"Rapamycin inhibits transforming growth factor beta-induced peritoneal angiogenesis by blocking the secondary hypoxic response","volume":"16","author":"Sekiguchi","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"107374","DOI":"10.1016\/j.intimp.2021.107374","article-title":"Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-\u03b2\/Smad signaling","volume":"93","author":"Shentu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-Van","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"173076","DOI":"10.1016\/j.ejphar.2020.173076","article-title":"GSK343, an inhibitor of EZH2, mitigates fibrosis and inflammation mediated by HIF-1\u03b1 in human peritoneal mesothelial cells treated with high glucose","volume":"880","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: Insights from the CREDENCE trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.biopha.2018.10.106","article-title":"SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2","volume":"109","author":"Zhou","year":"2019","journal-title":"Pharmacother"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1152611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:06:24Z","timestamp":1683875184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1152611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":29,"alternative-id":["10.3389\/fphar.2023.1152611"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1152611","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"article-number":"1152611"}}